About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in North Carolina | 20,428 Studies Near You | Clareo Health

Clinical Trials LocationsNorth Carolina

Clinical Trials in North Carolina

Discover 20,428 clinical trials near North Carolina. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 11941-11960 of 20,428 trials

COMPLETEDPhase 325 miles

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937

The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.

Papulopustular RosaceaErythematotelangiectatic Rosacea

bioRASI, LLC963 participantsStarted Feb 2015

Los Angeles, California, United States • San Diego, California, United States • Boca Raton, Florida, United States +24 more locations

COMPLETEDPhase 341 miles

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year

NCT02496767

This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.

Amyotrophic Lateral Sclerosis

Cytokinetics744 participantsStarted Sep 2015

Phoenix, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +78 more locations

Find Trials by Condition in North Carolina

Breast Cancerin North Carolina Lung Cancerin North Carolina Prostate Cancerin North Carolina Colorectal Cancerin North Carolina Melanomain North Carolina Leukemiain North Carolina Lymphomain North Carolina Pancreatic Cancerin North Carolina Ovarian Cancerin North Carolina Brain Cancerin North Carolina

Data from ClinicalTrials.govTerms

COMPLETEDPhase 341 miles

18F-AV-1451 Autopsy Study

NCT02516046

This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.

Alzheimer's Disease

Avid Radiopharmaceuticals156 participantsStarted Sep 2015

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Los Gatos, California, United States +28 more locations

COMPLETEDEARLY Phase 146 miles

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

NCT01875666

Kinases are a group of proteins that are important in how cancer cells grow. HER2 is a kind of kinase. This study looks at a new approach to identifying kinases, which may help target therapy more precisely. LCCC1214 is a randomized, multiarm, multicenter, open-label window trial designed to explore the kinome response in Stage I-IV HER2 positive (HER2+) breast cancer patients scheduled to undergo definitive surgery (either lumpectomy, mastectomy or surgical resection of oligometastatic disease). Patients will initiate dosing with either a single HER2-directed agent or a combination of two HER2-directed agents, one week prior to surgery. Forty patients will be randomized to one of four study groups: A) single dose trastuzumab; B) single dose pertuzumab; C) combination single dose trastuzumab plus single dose pertuzumab; or D) combination single dose trastuzumab plus lapatinib daily for 7 days. Pre- and post- dosing tissue will be analyzed for kinome response and resistant signatures. The initiation of study drug will be defined by the surgical schedule; there will be no delays in standard treatment for the purposes of this study.

Breast Neoplasms

UNC Lineberger Comprehensive Cancer Center26 participantsStarted Aug 2013

Birmingham, Alabama, United States • Indianapolis, Indiana, United States • Boston, Massachusetts, United States +2 more locations

TERMINATEDPhase 246 miles

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

NCT03241810

This study is a multi-center, randomized, double-blind, placebo-controlled, Phase 2 study in postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative metastatic, unresectable breast cancer.

Metastatic Breast Cancer

Elevation Oncology22 participantsStarted Aug 2017

Chandler, Arizona, United States • Fayetteville, Arkansas, United States • Beverly Hills, California, United States +56 more locations

COMPLETEDNA46 miles

Conventional Bite Wing Radiography Versus Stationary Intraoral Tomosynthesis, a Comparison Study

NCT02873585

A comparison of caries detection rates between conventional intraoral bitewing radiography and a stationary intraoral digital tomosynthesis (s-IOT) using a carbon nanotube X-ray source array. The secondary objective is to assess participants experience with the s-IOT device.

University of North Carolina, Chapel Hill32 participantsStarted Apr 2018

Chapel Hill, North Carolina, United States

COMPLETEDPhase 1/257 miles

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

NCT02586233

This is a Phase 1b/2, double-blind (study participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in participants with Acute Ischemic Stroke (AIS).

Acute Ischemic StrokeThrombotic Disease

Daiichi Sankyo106 participantsStarted Sep 2015

Mobile, Alabama, United States • Los Angeles, California, United States • Colorado Springs, Colorado, United States +52 more locations

COMPLETEDPhase 3114 miles

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

NCT02431806

The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran.

Major Depressive Disorder

Forest Laboratories552 participantsStarted Jun 2015

Dothan, Alabama, United States • Tucson, Arizona, United States • Anaheim, California, United States +46 more locations

COMPLETEDPhase 1156 miles

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

NCT00959959

The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).

Prostate Cancer

LTN PHARMACEUTICALS, INC.49 participantsStarted Oct 2009

Los Angeles, California, United States • San Bernardino, California, United States • Baltimore, Maryland, United States +5 more locations

COMPLETEDPhase 1186 miles

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

NCT01711515

This phase I trial studies the side effects and best dose of ipilimumab when given after chemoradiation therapy in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as ipilimumab, may find tumor cells and help carry tumor-killing substances to them. Giving ipilimumab together with chemoradiation therapy may be a better way treat cervical cancer.

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise Specified+6 more

National Cancer Institute (NCI)34 participantsStarted Oct 2012

Los Angeles, California, United States • Los Angeles, California, United States • Orange, California, United States +13 more locations

COMPLETEDPhase 3232 miles

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

NCT00948428

At the end of the study, safety and efficacy outcome measures will be compared to determine a) if dosing with Generic Imiquimod cream, 5% is therapeutically equivalent to the currently marketed Aldara (imiquimod) cream, 5% and b) if both imiquimod 5% creams are superior in comparison to the Vehicle cream.

Actinic Keratoses

Actavis Inc.462 participantsStarted May 2008

Hot Springs, Arkansas, United States • Fresno, California, United States • San Diego, California, United States +17 more locations

COMPLETEDPhase 2291 miles

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

NCT01090921

This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease. VELCADE® (bortezomib) for Injection is a drug under development by Millennium Pharmaceuticals, Inc.

Multiple Myeloma

Boston VA Research Institute, Inc.50 participantsStarted May 2007

Little Rock, Arkansas, United States • Los Angeles, California, United States • San Francisco, California, United States +8 more locations

COMPLETEDPhase 2308 miles

A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

NCT01395004

The purpose of this study was to assess safety and efficacy at months 3 and 6 in patients with Langerhans Cell Histiocytosis given daily oral doses of GSK2110183.

Langerhans Cell Histiocytosis

GlaxoSmithKline17 participantsStarted Nov 2011

Baltimore, Maryland, United States • Boston, Massachusetts, United States • New York, New York, United States +2 more locations

TERMINATEDPhase 2381 miles

Renal AL Amyloid Involvement and NEOD001

NCT03168906

This is a multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who have a maintained hematologic response to their most recent treatment for AL amyloidosis (e.g., chemotherapy, autologous stem cell transplant \[ASCT\]) and have persistent renal dysfunction.

Tufts Medical Center12 participantsStarted Jul 2017

Scottsdale, Arizona, United States • San Francisco, California, United States • Jacksonville, Florida, United States +6 more locations

TERMINATEDPhase 1392 miles

A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian

NCT01952249

This is a Phase 1b/2 study of paclitaxel plus demcizumab in subjects with platinum resistant ovarian, primary peritoneal or fallopian tube cancer.

Primary Peritoneal Carcinoma

OncoMed Pharmaceuticals, Inc.20 participantsStarted Aug 2013

Oklahoma City, Oklahoma, United States • Philadelphia, Pennsylvania, United States • Houston, Texas, United States

TERMINATEDPhase 1392 miles

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

NCT03597282

The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma. The study will also investigate an alternative schedule for the administration of the NEO-PV-01 vaccine. Study interventions will be assessed by both clinical and immune responses to treatment.

Metastatic Melanoma

BioNTech US Inc.22 participantsStarted Oct 2018

Scottsdale, Arizona, United States • Los Angeles, California, United States • Denver, Colorado, United States +5 more locations

TERMINATEDPhase 1472 miles

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

NCT01948297

This study is primarily designed to assess the safety and the tolerability of Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 genes, for whom standard treatment does not exist or is not indicated. The main objective of Part A is to identify the dose-limiting toxicities (DLTs) and estimate the maximum tolerated dose (MTD) based on the safety and tolerability of Debio1347 orally administered daily to these patients, in order to determine the recommended dose. The main objective of Part B is to evaluate the safety profile at the recommended dose, in a larger cohort of these patients.

Debiopharm International SA77 participantsStarted Aug 2013

Boston, Massachusetts, United States • Boston, Massachusetts, United States • New York, New York, United States +5 more locations

COMPLETEDPhase 1540 miles

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

NCT01992380

This study will test if two flortaucipir PET scans up to 4 weeks apart in healthy volunteers, MCI and AD subjects provide the same results.

Alzheimer's Disease

Avid Radiopharmaceuticals24 participantsStarted Nov 2013

Newport Beach, California, United States • New Haven, Connecticut, United States

COMPLETEDPhase 1/2660 miles

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

NCT01931046

The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3 in patients with localized prostate cancer.

Localized Prostate Cancer

Momotaro-Gene Inc.28 participantsStarted Oct 2013

San Diego, California, United States • Boston, Massachusetts, United States • Houston, Texas, United States

COMPLETEDPhase 3709 miles

An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

NCT00799266

This study was designed to evaluate the efficacy and safety of zoledronic acid compared to placebo in osteoporotic children treated with glucocorticoids

Novartis Pharmaceuticals34 participantsStarted Dec 2008

Westmead, New South Wales, Australia • Vancouver, British Columbia, Canada • Winnipeg, Manitoba, Canada +9 more locations

PreviousPage 598 of 1022Next

Diabetes

in North Carolina

Heart Diseasein North Carolina